Eli Lilly will now sell weight loss drugs directly to consumers. In a big move, the drugmaker has announced LillyDirect, a platform that uses telehealth to improve consumer access to weight loss drugs like Lilly’s Mounjaro and its recently approved Zepbound. CNBC’s Bertha Coombs explains the impact LillyDirect will have on health care and on pharmacy benefit providers like those of CVS, UnitedHealth, and Cigna. Primary care physician Dr. Kavita Patel underscores the health care access problem that millions of Americans face, and whether Eli Lilly’s effort could alleviate some of those pressures. Plus, CNBC’s Jon Fortt sees Apple’s 2024 going two very different directions after 2023’s stock strength and sales weakness. Microsoft keyboards are ready for their biggest change in almost 30 years, and the market’s Santa Claus rally is officially behind us–maybe. Bertha Coombs - 14:05 Dr. Kavita Patel - 24:11 Jon Fortt - 31:22 In this episode: Dr. Kavita Patel, @kavitapmd Bertha Coombs, @berthacoombs Jon Fortt, @jonfortt Becky Quick, @BeckyQuick Michael Santoli, @michaelsantoli Steve Liesman, @steveliesman Katie Kramer, @Kramer_Katie